share_log

加科思(01167.HK)展示JAB-3312與戈來雷塞聯用臨床前數據

Finet News ·  Oct 9, 2024 02:19

【財華社訊】加科思(01167.HK)公佈,公司在2024年第五屆RAS倡議研討會(the Fifth RAS Initiative Symposium 2024)上以壁報形式展示了SHP2抑制劑JAB-3312和KRAS G12C抑制劑戈來雷塞抑制劑聯用的臨床前數據。

數據證明,戈來雷塞和JAB-3312在體外和體內實驗均表現出強大的抗腫瘤作用,JAB-3312增強了戈來雷塞的抗腫瘤作用。壁報中還包括了有代表性患者病例。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 317

Recommended

Write a comment

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.